CAS 1245907-03-2: 3-Pyridinecarbonitrile, 2-[(5-hydroxy-1,5-dimethylhexyl)amino]-4-methyl-6-[(5-methyl-1H-pyrazol-3-yl)amino]-, hydrochloride (1:1)

TC-A 2317 HCl inhibits Aurora A kinase (Ki 1.2 nM) over Aurora B (Ki 101 nM), displaying antitumor effects.

TC-A2317 hydrochloride is a selective nicotinic acetylcholine receptor (nAChR) agonist, which is synthesized through chemical methods. It acts by specifically targeting nAChRs, which are ionotropic receptors predominantly found in the central nervous system and peripheral nervous system. These receptors are ligand-gated ion channels that, upon activation by agonists like TC-A2317 hydrochloride, result in increased neuronal excitability and neurotransmitter release. The primary utility of TC-A2317 hydrochloride lies in its application within neuroscientific and pharmacological research. It is used to study the modulation of synaptic transmission and the role of nAChRs in neurophysiological processes. The compound facilitates the exploration of neuronal signaling pathways and has implications for understanding diseases linked to cholinergic dysfunction, such as Alzheimer's and Parkinson's disease. Additionally, it serves as a tool in the development of therapeutic strategies focusing on nicotinic receptor modulation. Its selectivity and potency make it an invaluable asset in dissecting the functional contributions of specific nAChR subtypes.